Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Piceatannol and mTOR inhibitor combination proves be an attractive therapeutic strategy for gastric cancer

This study is led by Dr. Longtao Huangfu, and Dr. Xiaoyang Wang (Peking University Cancer Hospital & Institute). A diet of fresh fruits and vegetables may reduce the prevalence of cancers, including GC (Eusebi et al., 2020; Liu et al., 2021).

28 Oct 2022

Largest academic collaboration aims to transform the treatment for pediatric cancers

The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and St. Jude Children's Research Hospital today announced the largest academic collaboration of its kind to transform and accelerate the identification of vulnerabilities in pediatric cancers and translate them into better treatments.

13 Oct 2022

Signal transduction via the EGFR pathway likely to be involved in lenvatinib resistance

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become resistant to lenvatinib remain poorly understood. In this study, we demonstrated, for the first time, that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells.

14 Sep 2022

New biomimetic formulation developed to tackle glioblastoma multiforme

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore urgently needed.

22 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

UH experts in cloning and stem cell science take the first step toward unraveling cystic fibrosis

Two nationally recognized experts in cloning and stem cell science from the University of Houston are taking the first step toward limiting the consequences of chronic inflammation in cystic fibrosis (CF) by identifying the source of this persistent and enigmatic inflammation in CF lungs.

24 May 2022

Anti-Müllerian hormone plays an active role in polycystic ovary syndrome

High levels of anti-Mullerian hormone (AMH) have traditionally been thought of as merely a passive byproduct of polycystic ovary syndrome (PCOS), but a new preclinical study by Weill Cornell Medicine researchers suggests that the hormone plays an active role in the disorder and may contribute to problems with ovulation and fertility.

10 Mar 2022

New, highly promising strategy to overcome a key cause of cancer deaths

A research team led by scientists at Albert Einstein College of Medicine has devised a novel and highly promising strategy for overcoming a key cause of cancer deaths: the ability of cancer cells to thrive in the face of chemotherapy drugs designed to destroy them.

7 Mar 2022

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM.

22 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

UCLA study provides new insights into molecular 'crosstalk' in pancreas cancer cells

Research led by scientists at the Jonsson Comprehensive Cancer Center (JCCC) at UCLA provides new insights into molecular "crosstalk" in pancreas cancer cells, identifying vulnerabilities that could provide a target for therapeutic drugs already being studied in several cancers.

12 Jan 2022

MAPK4 may play a key role in triple-negative breast cancer

Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly.

12 Jan 2022

Study reveals chromosome-level changes that relate to drug resistance in melanoma

Precision therapies targeting melanoma and other cancers have improved patient survival, but tumors often stop responding to drugs, and recent studies point to changes in DNA – both inside and outside chromosomes – as a driving factor in tumor genesis as well as in treatment resistance.

20 Dec 2021

New genetic technology for gene expression analysis of cancer cells

In this interview, News-Medical speaks to Dr. Rong Lu about her recent research into the development of a new genetic technology for gene expression analysis of cancer cells.

3 Dec 2021

Machine learning analysis of long non-coding RNAs reveals new prognostic cancer biomarkers

A new batch of prognostic cancer biomarkers have been discovered in an area where few have gone looking before. Researchers have unveiled a catalogue of 166 prognostic biomarkers, generated by analyzing long non-coding RNAs (lncRNAs) – which are understudied in cancer research.

15 Nov 2021

Researchers develop ferritin-based nanomedicine for targeted delivery of leukemia therapy

Researchers from the Institute of Process Engineering\ of the Chinese Academy of Sciences, Peking University and Zhujiang Hospital of Southern Medical University have developed a ferritin (Fn)-based nanomedicine for targeted delivery of arsenic (As) and efficient therapy against diverse leukemia types.

25 Oct 2021

Study identifies specific small RNA molecule that can reduce levels of cancer-promoting gene

In a recent study published in CANCER RESEARCH , a team led by researchers at Tokyo Medical and Dental University (TMDU) identified a specific small RNA molecule, called a microRNA (miRNA or miR), that has the potential to be used as an anti-cancer therapeutic.

5 Oct 2021

CXCR6/CXCL16 axis has significant role in the immuno-pathogenesis of severe COVID-19

In a study published on the preprint server medRxiv*, scientists studying the SARS-CoV-2 genome have identified a region linked with the disease severity.

16 Sep 2021

BAK/MCL1 complex in tumor cells can predict the sensitivity of chemotherapy drugs in ovarian cancer

A research team led by Prof. DAI Haiming from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences (CAS) recently announced the constitutive BAK/MCL1 complexes could predict chemotherapy drugs sensitivity of ovarian cancer. The result has been published on Cell death & disease.

16 Sep 2021

Combination therapy disables PI3K/Akt/mTOR pathway and induces apoptosis in carcinoid syndrome

Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.

28 Aug 2021

Xenograft News and Research

Piceatannol and mTOR inhibitor combination proves be an attractive therapeutic strategy for gastric cancer

Largest academic collaboration aims to transform the treatment for pediatric cancers

Signal transduction via the EGFR pathway likely to be involved in lenvatinib resistance

New biomimetic formulation developed to tackle glioblastoma multiforme

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

UH experts in cloning and stem cell science take the first step toward unraveling cystic fibrosis

Anti-Müllerian hormone plays an active role in polycystic ovary syndrome

New, highly promising strategy to overcome a key cause of cancer deaths

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

UCLA study provides new insights into molecular 'crosstalk' in pancreas cancer cells

MAPK4 may play a key role in triple-negative breast cancer

Study reveals chromosome-level changes that relate to drug resistance in melanoma

New genetic technology for gene expression analysis of cancer cells

Machine learning analysis of long non-coding RNAs reveals new prognostic cancer biomarkers

Researchers develop ferritin-based nanomedicine for targeted delivery of leukemia therapy

Study identifies specific small RNA molecule that can reduce levels of cancer-promoting gene

CXCR6/CXCL16 axis has significant role in the immuno-pathogenesis of severe COVID-19

BAK/MCL1 complex in tumor cells can predict the sensitivity of chemotherapy drugs in ovarian cancer

Combination therapy disables PI3K/Akt/mTOR pathway and induces apoptosis in carcinoid syndrome

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News